Table 1.

Selected Oncotype DX Clinical Studies¹⁰ and Other Events in Figure 1

Study or Guideline	Description	Date of Announcement or Publication
Kaiser validation study20	Validation study among 4,964 Kaiser patients	December 2004, 27th San Antonio Breast Cancer Symposium
B14 validation study21	Validation study of 668 patients in NSABP B-14 trial	December 2004, New England Journal of Medicine
B20 validation study22	Validation study of 651 patients in NSABP B-20 trial	May 2005, 41st ASCO Annual Meeting
Local Medicare coverage decision17	Contractor in California grants coverage of Oncotype DX	January 2006
Rocky Mountain utility study23	Retrospective analysis of clinical utility of Oncotype DX affecting chemotherapy decisions for 68 patients	December 2005, 28th San Antonio Breast Cancer Symposium
Intergroup E2197 validation study24	Validation study of 776 patients in Intergroup E2197 trial	June 2007, 43rd ASCO Annual Meeting
Mayo utility study25	Analysis of clinical utility of Oncotype DX affecting chemotherapy decisions for 31 Mayo patients	June 2007, 43rd ASCO Annual Meeting
TAILORx study15	Large prospective study of clinical validity, utility, and health outcomes of Oncotype DX	Launched May 2006
Loyola study26,27 of clinical utility	Prospective study of clinical utility of Oncotype Dx in 89 patients	June 2007, 43rd ASCO Annual Meeting
Inclusion in ASCO recommendations18	ASCO update recommends Oncotype Dx	November 2007
Inclusion in NCCN guidelines19	NCCN clinical guidelines include Oncotype DX	January 2008

Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel Project; TAILORx, Trial Assigning IndividuaLized Options for Treatment (Rx); NCCN, National Comprehensive Cancer Network.